CCO Treatment Updates
Navigating Multiple Pathways: Evolving Options and Future Directions in Targeted Therapies
Clinical Evidence: What Have We Learned From Targeting EGFR? |
Module 1 of 3 |
|
CME Program Director: Manuel Hidalgo, MD, PhD
|
|
Louis M. Weiner, MD, reviews current clinical trial data regarding EGFR-targeted therapeutic agents in the treatment of cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the biologic activity of EGFR
- Summarize the use of tyrosine kinase inhibitors and monoclonal antibodies in the treatment of EGFR-overexpressing cancers
- Review strategies for improving the efficacy of targeted anti-EGFR agents
|
Multitargeted Tyrosine Kinase Inhibitors: When Are More Targets Necessary? |
Module 2 of 3 |
|
Program Director: Manuel Hidalgo, MD, PhD
|
|
Lee S. Rosen, MD, discusses the central role VEGF plays in tumor angiogenesis, and how this and additional targets have been exploited in the development of tyrosine kinase inhibitors.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the role of vascular endothelial growth factor (VEGF) in tumor growth and survival
- Identify emerging targeted therapies that have shown activity in the treatment of a various solid tumors
- List differentiating factors between monoclonal antibodies and small-molecule kinase inhibitors targeting the VEGF pathway
- Describe the rationale behind the use of kinase inhibitors that target multiple pathways
|
Targeting the Tumor Microenvironment: How Is It Useful? |
Module 3 of 3 |
|
Program Director: Manuel Hidalgo, MD, PhD
- John R. Mackey, MD, FRCP(C)
|
|
|
John R. Mackey, MD, FRCP(C), discusses the critical role of the tumor microenvironment and how targeting these components is useful in combating cancer progression.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Explain the cellular signaling inhibition achieved by targeting the tumor microenvironment
- Describe therapeutic approaches to targeting the bone microenvironment
- Identify future possible approaches to targeting the tumor microenvironment
|
CCO Slidesets
Clinical Evidence: What Have We Learned From Targeting EGFR?
 |
|
Animations: View in slide show to see the graphics evolve.
Format: Microsoft PowerPoint (.ppt) |
File size: 4.05 MB
|
Multitargeted Tyrosine Kinase Inhibitors: When Are More Targets Necessary?
 |
|
Animations: View in slide show to see the graphics evolve.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.86 MB
|
Targeting the Tumor Microenvironment: How Is It Useful?
 |
|
Animations: View in slide show to see the graphics evolve.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.06 MB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
This activity is supported by an educational donation provided by
Educational grants support only the CME-certified components of this program.
|
|